Fulgent (FLGT) Q2 Revenue Jumps 16%
Fulgent Genetics (NASDAQ:FLGT), a genomic testing company focused on precision diagnostics and therapeutic development, reported better-than-expected results in its Q2 2025 earnings release dated August 1, 2025. The company posted GAAP revenue of $81.8 million, comfortably surpassing the analyst consensus GAAP revenue estimate of $76.2 million. On a non-GAAP basis, earnings per share reached $0.07, outperforming the anticipated $(0.18) non-GAAP loss. These results reflected strong momentum in the Laboratory Services business and translated into a raised full-year 2025 core revenue outlook of $320.0 million. However, despite the top-line and non-GAAP earnings outperformance, Fulgent reported a wider GAAP loss due to a one-time impairment. The quarter highlighted revenue growth, margin improvements, and strategic progress, balanced against rising operating expenses and ongoing GAAP losses.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Fulgent Genetics is a company specializing in precision diagnosis through advanced genetic testing and the development of innovative therapeutics. It operates with two main business pillars: Laboratory Services, which delivers a broad menu of genetic and diagnostic tests using proprietary technology, and Therapeutic Development, which focuses on new cancer treatments using nanoencapsulation platforms for more effective drug delivery.
Source Fool.com
